Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT06813664
Starting soon Phase 2

ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)

NCT06813664 · tracked via the Priya Life Science Canada tracker
Phase
Phase 2
Started
2026-09-01
Last updated
2026-08-13

Condition(s) studied

Metastatic NSCLC - Non-Small Cell Lung CancerOligoProgressive Metastatic Disease

Investigational drug(s) / intervention(s)

RadiotherapyRadiotherapy

Radiotherapy: SBRT/high-dose radiotherapy Standard of care targeted therapy

Radiotherapy: SBRT/high-dose radiotherapy Second-line targeted therapy

Study summary

This is an open-label, prospective single arm Phase II trial that investigates the role of ablative stereotactic body radiation therapy (SBRT) in oncogene driven metastatic non-small cell lung cancer (mNSCLC) patients with oligoprogressive disease (OPD) on targeted therapy (TKI) followed by circulating tumor DNA (ctDNA) analysis for tailoring targeted therapies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age 18 or older. 2. Able to do most daily activities (ECOG 0-2). 3. Able and willing to sign an informed consent form to join the study. 4. Metastatic disease detected on imaging and histologically confirmed NSCLC on first-line TKI therapy 5. Willing to give a blood sample for ctDNA analysis. 6. No upper limit to the number of total metastatic sites, but a maximum of five progressive metastatic sites, inclusive of primary disease and metastatic lesions, all of which must be extracranial 7. Prior radiation therapy near progressive lesions is allowed if applicable. 8. All sites of oligoprogression that can be safely treated with SBRT or hypofractionated ablative radiotherapy 9. Oligoprogressive disease is evaluated independently for each lesion using specific criteria. 10. Stable brain metastases allowed if asymptomatic and do not require corticosteroids. 11. Oligoprogressive lesions previously treated with external beam radiation are eligible as long they are clinically asymptomatic, and re-treatment is possible according to the investigator. Prior conventional, non-stereotactic radiotherapy for palliative -purposes is allowed, and if the palliated lesion subsequently progressed but remains asymptomatic and does not require immediate radiotherapy, the lesion can still be counted toward one of the five oligoprogressive lesions 12. Participant is able (i.e. sufficiently fluent or with the assistance of a translator) and willing to complete the quality of life and/or health utility questionnaires in English 13. Accessible for treatment and follow-up. Exclusion Criteria: 1. More than 5 extracranial sites of progressive disease. 2. Pregnant. 3. Leptomeningeal disease. 4. Serious health issues that prevent radiotherapy, like ataxia-telangiectasia or scleroderma. 5. Prior radiation therapy near the progressive lesion that would prevent treatment with SBRT due to exceeding limits of healthy tissue tolerance. 6. Any other condition that the investigator believes makes participation in the study inappropriate.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network Toronto Ontario

More University Health Network, Toronto trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06813664 on ClinicalTrials.gov ↗ ← All trials in Canada